RxDoctor Payments Data

Erica Lyden

Psychiatric/Mental Health · Stroudsburg, PANPI 1073197786

Payments from drug & device makers

$3,432in general payments, 2019–2025

Across 151 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$565
  • Johnson & Johnson$496
  • Teva Pharmaceuticals USA, Inc.$452
  • AbbVie$400
  • Otsuka America Pharmaceutical, Inc.$398
  • Lundbeck LLC$389
  • plus $731 from 9 others

What the payments were for

  • Food & beverage$3,35798%
  • Education$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,432 in reported general payments places this provider in the 85th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$7,439
Medicare patients
14
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole15$23,018
VraylarCariprazine Hcl13$17,701
Gabapentin30$1,237
Bupropion XlBupropion Hcl48$878
Desvenlafaxine Succinate ErDesvenlafaxine Succinate16$759
Duloxetine Hcl22$467
Quetiapine Fumarate30$465
Lorazepam97$460
Clonazepam72$438
Bupropion Hcl14$415
Escitalopram Oxalate33$394
Trazodone Hcl42$336
Sertraline Hcl55$299
Benztropine Mesylate21$277
Bupropion Hcl SrBupropion Hcl17$275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$398$23,01815 claims
AbbVieVraylar$400$17,70113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Stroudsburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →